PannTherapi Announces the approval of its Phase 2a study to evaluate PannTheraPi’s first-in-class Pannexin 1-targeting therapy in patients with drug-resistant Focal Cortical Dysplasia, a rare and severe form of epilepsy.

Link to the Press Release:

https://www.globenewswire.com/news-release/2026/09/08/3357332/0/en/panntherapi-receives-ansm-approval-to-advance-pti5803-into-phase-2a-in-focal-cortical-dysplasia.html